VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCF
176
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
| $595K | 0.29% |
67,209
+14,764
| +28% | +$131K |
|
177
Invesco Quality Municipal Securities
IQI
$502M
| $520K | 0.25% |
52,429
+13,957
| +36% | +$138K |
|
178
Monroe Capital Corp
MRCC
$164M
| $508K | 0.25% |
66,748
+17,088
| +34% | +$130K |
|
179
Alnylam Pharmaceuticals
ALNY
$59.2B
| $500K | 0.24% |
2,058
+15
| +0.7% | +$3.65K |
|
|
BCIC
180
BCP Investment Corporation Common Stock
BCIC
$160M
| $500K | 0.24% |
25,488
+5,899
| +30% | +$116K |
|
181
Oxford Square Capital
OXSQ
$171M
| $470K | 0.23% |
159,850
+42,254
| +36% | +$124K |
|
182
OFS Capital
OFS
$116M
| $452K | 0.22% |
50,922
+19,198
| +61% | +$170K |
|
183
Mirum Pharmaceuticals
MIRM
$3.73B
| $422K | 0.21% |
12,344
+1,329
| +12% | +$45.4K |
|
184
Sarepta Therapeutics
SRPT
$1.94B
| $416K | 0.2% |
2,635
-1,396
| -35% | -$221K |
|
185
Ionis Pharmaceuticals
IONS
$9.4B
| $382K | 0.19% |
8,009
+361
| +5% | +$17.2K |
|
186
Ardelyx
ARDX
$1.57B
| $376K | 0.18% |
50,747
+35,807
| +240% | +$265K |
|
187
Travere Therapeutics
TVTX
$1.85B
| $374K | 0.18% |
45,490
+1,340
| +3% | +$11K |
|
188
Axsome Therapeutics
AXSM
$6.19B
| $366K | 0.18% |
4,542
-658
| -13% | -$53K |
|
189
United Therapeutics
UTHR
$17.2B
| $365K | 0.18% |
1,145
-355
| -24% | -$113K |
|
190
Ironwood Pharmaceuticals
IRWD
$185M
| $359K | 0.18% |
55,075
+21,798
| +66% | +$142K |
|
191
Insmed
INSM
$30B
| $358K | 0.18% |
5,344
-7,849
| -59% | -$526K |
|
192
Gilead Sciences
GILD
$140B
| $356K | 0.17% |
5,182
+523
| +11% | +$35.9K |
|
193
Acadia Pharmaceuticals
ACAD
$4.33B
| $355K | 0.17% |
21,826
+8,247
| +61% | +$134K |
|
194
ImmunityBio
IBRX
$2.25B
| $355K | 0.17% |
56,107
+34,817
| +164% | +$220K |
|
195
Aurinia Pharmaceuticals
AUPH
$1.65B
| $352K | 0.17% |
61,561
+19,366
| +46% | +$111K |
|
196
Ascendis Pharma
ASND
$12.1B
| $351K | 0.17% |
2,576
-596
| -19% | -$81.3K |
|
197
Day One Biopharmaceuticals
DAWN
$752M
| $351K | 0.17% |
25,491
+19,413
| +319% | +$268K |
|
198
TG Therapeutics
TGTX
$4.96B
| $350K | 0.17% |
19,651
+14,836
| +308% | +$264K |
|
199
Halozyme
HALO
$8.61B
| $348K | 0.17% |
6,637
-3,022
| -31% | -$158K |
|
200
Amgen
AMGN
$151B
| $345K | 0.17% |
1,103
-278
| -20% | -$86.9K |
|